Status:
ACTIVE_NOT_RECRUITING
Developing Microbials to Fight Extended-spectrum Beta-lactamase (ESBL)-Producing Escherichia Coli
Lead Sponsor:
University Hospital, Basel, Switzerland
Collaborating Sponsors:
Gebert Rüf-Stiftung
Conditions:
Extended Spectrum Beta Lactamases (ESBL) E. Coli
Eligibility:
All Genders
18+ years
Brief Summary
This study is to identify and isolate well-defined microbials (non-ESBL E. coli) in an observational setting exploring natural gastrointestinal decolonization of humans colonized with ESBL E. coli.
Detailed Description
Antibiotic resistance is a severe threat to contemporary medicine. Effective approaches to fight multi-drug resistant pathogenic bacteria are needed. This clinical observational study is to investiga...
Eligibility Criteria
Inclusion
- travelling to Southeast Asia (India, Bhutan, Nepal, Bangladesh, Myanmar, Thailand, Laos, Cambodia, Vietnam) for a maximum of 4 weeks.
Exclusion
- other travelling destinations than mentioned above
- antibiotic use at the first sampling time
- Participants who are not colonized will serve as a control group for microbiome comparison
Key Trial Info
Start Date :
June 13 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2025
Estimated Enrollment :
39 Patients enrolled
Trial Details
Trial ID
NCT04764500
Start Date
June 13 2019
End Date
December 1 2025
Last Update
March 3 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Basel, Division of Clinical Microbiology
Basel, Switzerland, 4031